「pr」の検索結果
238件：151～155件目を表示
-
April 6, 2026 General Announcement Senju Pharmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Launch of “Avarept® Ophthalmic Suspension 0.3%” in Japan, A Novel Treatment of Dry Eye Disease throug...
https://www.senju.co.jp/system/files/content_news/2026-04/ENG_20260406.pdf -
April 6, 2026 General Announcement Senju Pharmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Launch of “Avarept® Ophthalmic Suspension 0.3%” in Japan, A Novel Treatment of Dry Eye Disease throug...
https://www.senju.co.jp/system/files/content_news/2026-04/ENG_20260406_0.pdf -
忌です。 ■参考 米国FDAの亜硫酸塩を含有する医療用医薬品による過敏症に関する医療関係者向けの注意喚起の内容 を、以下のサイトよりご確認いただけます。 FDA alerts health care professionals, compounders and patients of potential safety risks associated with sulfite- containin...
https://www.senju.co.jp/system/files/news_file/2026-03/BRN_202603_Revised Info.pdf -
vel Dry Eye Disease treatment, SJP-0132 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a compound (development code: SJP-0...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240716_0.pdf -
vel Dry Eye Disease treatment, SJP-0132 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter: Senju) is developing a compound (development code: SJP-0...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240716.pdf